SEC Form 4 · accession 0001240801-26-000004
Inhibrx Biosciences, Inc. · INBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Forsyth
Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 8, 2026 · 4:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002007919
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 8, 2026 | P | 2,500 | $114.6469 | A | 227,064 | I | By the Forsyth Family Trust Dated July 20, 2001 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were purchased in multiple transactions at prices ranging from $114.36 to $114.689 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001.